[Translation] A multicenter, open-label Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-295S1 in the treatment of patients with advanced malignant solid tumors
1.评价HMPL-295S1单药口服治疗晚期实体瘤患者的安全性和耐受性;
2.确定HMPL-295S1单药口服在晚期实体瘤患者中的最大耐受剂量(MTD)和/或II期临床研究推荐剂量(RP2D)。
[Translation] 1. Evaluate the safety and tolerability of oral monotherapy of HMPL-295S1 in patients with advanced solid tumors;
2. Determine the maximum tolerated dose (MTD) and/or recommended dose (RP2D) of oral monotherapy of HMPL-295S1 in patients with advanced solid tumors.